MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Fluorescence-lifetime ophthalmoscopy findings in Parkinson’s disease patients with visual disturbances

K. Shivok, E. Affel, M. Alizadeh, T-W. Liang, D. Kremens, R. Sergott (Philadelphia, USA)

Meeting: 2023 International Congress

Abstract Number: 519

Keywords: Parkinson’s, Visuospatial deficits

Category: Parkinson's Disease: Non-Motor Symptoms

Objective: We identified fluorescence-lifetime ophthalmoscopy changes in Parkinson’s disease (PD) patients experiencing visual disturbances.

Background: Fluorescence-lifetime ophthalmoscopy (FLIO), a novel in vivo imaging method generating data for fluorescence decay in two spectral channels.  After an excitation frequency of 473 nm, FLIO acquires data from two channels of very short-lived chromophores: Channel 1 @ 498-560nm corresponding mostly to Nicotinamide adenosine dinucleotide hydrogen (“NADH”) and Flavin adenine dinucleotide (“FAD”) and channel 2 @ 560-720 nm corresponding primarily to lipofuscin. These data reflect the mitochondrial molecular environment.

Method: Eighteen participants [36 eyes], 9 PD patients experiencing visual disturbances and 9 controls, underwent FLIO imaging. Imaging was analyzed using SPCImage technology. The amplitude-weighted mean fluorescence decay time (τm) and mean channel wavelength were analyzed quantitatively using a nonparametric test based on Wilcoxon rank sum test followed by Steel-Dwass for post-hoc multiple comparisons.

Results: Significant differences were found in all mean channel wavelengths between PD patients and controls. Channels 1 and 2 for both eyes compared to controls displayed an overall right shift towards longer wavelengths. The amplitude-weighted mean fluorescence decay time was significantly (p<0.05) greater in channel 1 right eye, and channels 1 and 2 left eye.

Conclusion: FLIO detected changes consistent with alterations in the retinal mitochondrial molecular environment for both NADH and FAD as well as lipofuscin. FLIO is the only retinal imaging technique capable of detecting these changes. The FLIO data may help to explain the basis of visual disturbances in patients with PD. This technology, which is the in vivo equivalent of fluorescent lifetime imaging microscopy, may help to define mitochondrial dynamics in various stages of Parkinson’s Disease and may evolve into an objective biomarker for clinical trials.

To cite this abstract in AMA style:

K. Shivok, E. Affel, M. Alizadeh, T-W. Liang, D. Kremens, R. Sergott. Fluorescence-lifetime ophthalmoscopy findings in Parkinson’s disease patients with visual disturbances [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/fluorescence-lifetime-ophthalmoscopy-findings-in-parkinsons-disease-patients-with-visual-disturbances/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/fluorescence-lifetime-ophthalmoscopy-findings-in-parkinsons-disease-patients-with-visual-disturbances/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley